stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Net income
Smith & Nephew SNATS, Inc.'s net income for fiscal 2025 was $779.0M, up 56.4% from $498.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.0B. Over the past ten years it has ranged from $235.0M (fiscal 2022) to $1.1B (fiscal 2016); the current reading is higher than 73% of that period. Net income has risen for 3 consecutive fiscal years. Smith & Nephew SNATS, Inc. ranks 6th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $779.0M | 56.43% |
| FY2024 | $498.0M | 71.72% |
| FY2023 | $290.0M | 23.40% |
| FY2022 | $235.0M | (59.90%) |
| FY2021 | $586.0M | 138.21% |
| FY2020 | $246.0M | (66.89%) |
| FY2019 | $743.0M | (4.87%) |
| FY2018 | $781.0M | (11.15%) |
| FY2017 | $879.0M | (17.23%) |
| FY2016 | $1.1B | 89.98% |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | $2.0B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| GMED Globus Medical, Inc. compare | $557.6M |
| PODD Insulet Corporation compare | $428.8M |
| PEN Penumbra, Inc. compare | $157.0M |
| TXG 10x Genomics compare | −$75.1M |
| BRKR Bruker Corporation compare | −$115.7M |
| GKOS Glaukos Corporation compare | −$169.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SNN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement